Anktiva access in Pakistan: the DRAP named-patient pathway
How patients in the Islamic Republic of Pakistan legally obtain Anktiva (nogapendekin alfa inbakicept-pmln) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Ask about Anktiva in Pakistan
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
Quick orientation
Patients in Pakistan access Anktiva (nogapendekin alfa inbakicept-pmln) for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumours, in adults, given with BCG through the DRAP named-patient pathway, a Drug Regulatory Authority of Pakistan-administered mechanism that allows a Pakistani-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and how to get a written quote.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Reserved for you.
How Anktiva reaches patients in Pakistan
Anktiva (nogapendekin alfa inbakicept-pmln, an IL-15 receptor superagonist fusion protein from ImmunityBio, FDA-approved 22 April 2024 in combination with BCG for adults with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumours) is not currently visible on the DRAP registered-product verification portal at dra.gov.pk/e-services/online-data-verification as of 2026-06-01. Patients access Anktiva under the Special Permission for Import of Therapeutic Goods for Personal Use (the patient-named No Objection Certificate or NOC), administered by the Import and Export Section of the DRAP Quality Assurance and Laboratory Testing Division under the Drugs Act 1976 read with the Drugs (Import and Export) Rules 1976 and DRAP Guidance Document QALT/GL/IP/004 at dra.gov.pk Guidance. The application is filed online via the DRAP Special Permissions portal at dra.gov.pk Special Permissions. DRAP does not publish a fixed processing-time SLA; patient-org reporting indicates several working days when documentation is complete. For Anktiva specifically, the clinical justification must reference cystoscopy and biopsy confirmation of high-grade non-muscle invasive bladder cancer with carcinoma in situ, documented BCG-unresponsive disease per the FDA definition (persistent or recurrent CIS within 12 months of adequate BCG induction plus maintenance), the planned Anktiva plus BCG intravesical induction and maintenance schedule per the QUILT-3.032 phase 2 trial protocol (NCT03022825), the cystoscopic surveillance plan, and patient counselling on radical cystectomy as the alternative. The prescribing urologic oncologist must be registered with the Pakistan Medical and Dental Council. The NOC is single-consignment for the induction or maintenance cycle scaled to roughly three months of supply per the DRAP guidance convention; chronic urology maintenance therapy requires re-filing each shipment cycle. A parallel hospital-led pathway under the Special Permission for Institutional Import framework allows institutional importers to file on the prescribing physician's behalf.
Where Anktiva is dispensed in Pakistan
Site selection for Anktiva turns on a much shorter capability checklist than cell therapy: a urologist comfortable with cystoscopic intravesical instillation, a day-case bladder-instillation suite, refrigerated pharmacy storage at 2 to 8 degrees Celsius with continuous logging, and a co-administration plan for intravesical BCG. No certified-cell-therapy infrastructure, no lymphodepletion ward, and no ICU bed are required. The natural dispensing home in Pakistan is therefore the urology service rather than the medical-oncology service.
What Anktiva costs in Pakistan
Medicine price: quote on request. Every case gets a written custom quote before you commit. Cumulative cost depends on the cystoscopic-response-driven maintenance schedule (continued instillations every three months for the first year then reduced cadence for up to 37 months per the protocol). ImmunityBio US patient services do not extend to Pakistani residents. Co-administered BCG supply availability is a separate planning constraint and is sourced through the same DRAP institutional channel.
Funding and access barriers for Anktiva in Pakistan
The pivotal funding argument on a Pakistani Anktiva case is the cystectomy-alternative framing: the realistic comparator from the patient's perspective is radical cystectomy plus urinary diversion plus adjuvant pathway, a major surgical course, and the Anktiva-plus-BCG bladder-preserving alternative now has an FDA-labelled efficacy signal in BCG-unresponsive disease. Private insurers active in Pakistan do not list unlicensed drugs on retail formularies, but on group corporate policies the comparator-cost case is the one that opens pre-authorisation discussions, particularly where the policy already covers cystectomy. The Sehat Sahulat Programme at pmhealthprogramme.gov.pk remains scoped to in-network empaneled inpatient care rather than imported intravesical biologics, and the Khyber Pakhtunkhwa Sehat Card Plus, while the broadest provincial cover, has not historically reimbursed imported intravesical immunotherapy. Pakistan Bait-ul-Mal grants at pbm.gov.pk on the cancer track can defray a cycle or two of induction. The class-specific access barrier on Anktiva is not regulatory and not the drug invoice in isolation.
Recent regulatory and access news for Anktiva
DRAP published the consolidated Guidance Document for Applicants on Import and Export Permissions of Therapeutic Goods (QALT/GL/IP/004) covering personal-use, institutional, and donation imports, the current operative reference for any Anktiva NOC application; full notice at dra.gov.pk regulatory updates. The Federal Cabinet of Pakistan approved an exemption for the import of unregistered drugs in defined public-interest cases under Section 23 of the Drugs Act 1976, broadening the institutional-import lane for rare and oncology drugs not commercially available in Pakistan, reported at Express Tribune. On the manufacturer side, ImmunityBio continues post-marketing follow-up of the QUILT-3.032 cohort and label-expansion programmes for additional bladder-cancer subtypes; no DRAP-specific bulletin for Anktiva over the last 12 months has been observed as of 2026-06-01.
Where Reserve Meds fits in Anktiva cases
Reserve Meds is a US-based digital health company. We do not replace your treating physician, we do not replace DRAP, and we do not replace your dispensing pharmacy. For Anktiva specifically, we orchestrate supply through a US-licensed pharmaceutical wholesale partner, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Pakistan, and give you one point of contact through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.
Operationally, a typical Anktiva case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the DRAP application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the case coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.
Anktiva is delivered intravesically in combination with BCG on a defined induction-and-maintenance schedule; cystoscopic surveillance and BCG availability govern treatment continuity.
Next step
If your Pakistani physician has prescribed Anktiva and you are weighing the cross-border route, the next step is a short intake. We reply within one business day, then send a documentation checklist to your doctor.
Reserved for you.